Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
108 hedge funds and large institutions have $372M invested in Albireo Pharma Inc in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 45 increasing their positions, 27 reducing their positions, and 17 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 27
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
23% more call options, than puts
Call options by funds: $2.2M | Put options by funds: $1.79M
6% more capital invested
Capital invested by funds: $353M → $372M (+$19.5M)
5% more funds holding
Funds holding: 103 → 108 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$23M |
| 2 |
Millennium Management
New York
|
+$9.91M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$8.26M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$7.42M |
| 5 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$6.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$22.2M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$8.56M |
| 3 |
CC
Chicago Capital
Chicago,
Illinois
|
-$4.79M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$4.59M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.57M |
ALBO Hedge Fund Activity: Q3 2022 in Review
108 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q3 2022, worth a combined $372M — up 5.5% from $353M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ALBO positions and 17 closed out — a net gain of 5 holders — while 45 added to existing stakes and 27 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $23M. The largest seller was State Street, cutting an estimated $22.2M.
- 108 institutional investors held Albireo Pharma Inc (ALBO) as of Q3 2022, up from 103 in Q2 2022.
- Funds reported $372M of Albireo Pharma Inc stock for Q3 2022, up 5.5% quarter-over-quarter.
- 22 funds opened new Albireo Pharma Inc positions in Q3 2022 and 17 closed out, a net change of +5 holders.
- The largest Albireo Pharma Inc buyer in Q3 2022 was Deep Track Capital, an estimated $23M added.
- The largest Albireo Pharma Inc seller in Q3 2022 was State Street, an estimated $22.2M sold.
Based on aggregated 13F filings for Q3 2022.